Volume 60, Issue 10 pp. 5348-5356
Research Article

Potent Trivalent Inhibitors of Thrombin through Hybridization of Salivary Sulfopeptides from Hematophagous Arthropods

Dr. Stijn M. Agten

Dr. Stijn M. Agten

School of Chemistry and ARC Centre of Excellence for Innovations in Peptide and Protein Science, The University of Sydney, Sydney, 2006 NSW, Australia

Department of Biochemistry, Cardiovascular Research Institute Maastricht (CARIM), Maastricht University, Universiteitssingel 50, 6229 ER Maastricht, The Netherlands

Search for more papers by this author
Dr. Emma E. Watson

Dr. Emma E. Watson

School of Chemistry and ARC Centre of Excellence for Innovations in Peptide and Protein Science, The University of Sydney, Sydney, 2006 NSW, Australia

Search for more papers by this author
Dr. Jorge Ripoll-Rozada

Dr. Jorge Ripoll-Rozada

IBMC—Instituto de Biologia Molecular e Celular and Instituto de Investigação e Inovação em Saúde, Universidade do Porto, 4200-135 Porto, Portugal

Search for more papers by this author
Dr. Luke J. Dowman

Dr. Luke J. Dowman

School of Chemistry and ARC Centre of Excellence for Innovations in Peptide and Protein Science, The University of Sydney, Sydney, 2006 NSW, Australia

Search for more papers by this author
Dr. Mike C. L. Wu

Dr. Mike C. L. Wu

Charles Perkins Centre, The University of Sydney, Sydney, NSW, 2006 Australia

Heart Research Institute, Sydney, NSW, 2042 Australia

Search for more papers by this author
Imala Alwis

Imala Alwis

Charles Perkins Centre, The University of Sydney, Sydney, NSW, 2006 Australia

Heart Research Institute, Sydney, NSW, 2042 Australia

Search for more papers by this author
Prof. Shaun P. Jackson

Prof. Shaun P. Jackson

Charles Perkins Centre, The University of Sydney, Sydney, NSW, 2006 Australia

Heart Research Institute, Sydney, NSW, 2042 Australia

Search for more papers by this author
Dr. Pedro José Barbosa Pereira

Corresponding Author

Dr. Pedro José Barbosa Pereira

IBMC—Instituto de Biologia Molecular e Celular and Instituto de Investigação e Inovação em Saúde, Universidade do Porto, 4200-135 Porto, Portugal

Search for more papers by this author
Prof. Richard J. Payne

Corresponding Author

Prof. Richard J. Payne

School of Chemistry and ARC Centre of Excellence for Innovations in Peptide and Protein Science, The University of Sydney, Sydney, 2006 NSW, Australia

Search for more papers by this author
First published: 20 December 2020
Citations: 13

In memory of Chris Abell

Graphical Abstract

The rational design of a novel class of trivalent thrombin inhibitors is described through the hybridization of natural sulfopeptides produced by blood feeding organisms. The hybrid sulfopeptides were rapidly assembled using peptide ligation chemistry and shown to exhibit femtomolar inhibition constants against thrombin. A lead inhibitor also showed potent inhibition of thrombin generation and platelet aggregation in vitro, as well as antithrombotic effects in a murine model.

Abstract

Blood feeding arthropods, such as leeches, ticks, flies and mosquitoes, provide a privileged source of peptidic anticoagulant molecules. These primarily operate through inhibition of the central coagulation protease thrombin by binding to the active site and either exosite I or exosite II. Herein, we describe the rational design of a novel class of trivalent thrombin inhibitors that simultaneously block both exosites as well as the active site. These engineered hybrids were synthesized using tandem diselenide-selenoester ligation (DSL) and native chemical ligation (NCL) reactions in one-pot. The most potent trivalent inhibitors possessed femtomolar inhibition constants against α-thrombin and were selective over related coagulation proteases. A lead hybrid inhibitor possessed potent anticoagulant activity, blockade of both thrombin generation and platelet aggregation in vitro and efficacy in a murine thrombosis model at 1 mg kg−1. The rational engineering approach described here lays the foundation for the development of potent and selective inhibitors for a range of other enzymatic targets that possess multiple sites for the disruption of protein–protein interactions, in addition to an active site.

Conflict of interest

The authors declare no conflict of interest.

The full text of this article hosted at iucr.org is unavailable due to technical difficulties.